← Back to Screener
Rocket Pharmaceuticals, Inc. Common Stock (RCKT)
Price$3.86
Favorite Metrics
Price vs S&P 500 (26W)5.58%
Price vs S&P 500 (4W)-15.05%
Market Capitalization$421.21M
All Metrics
Book Value / Share (Quarterly)$2.56
P/TBV (Annual)1.51x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.76
Price vs S&P 500 (YTD)7.26%
EPS (TTM)$-2.01
10-Day Avg Trading Volume2.50M
EPS Excl Extra (TTM)$-2.01
EPS (Annual)$-2.01
ROI (Annual)-74.75%
Cash / Share (Quarterly)$1.74
ROA (Last FY)-67.52%
EBITD / Share (TTM)$-1.92
ROE (5Y Avg)-53.74%
Cash Flow / Share (Annual)$-1.76
P/B Ratio1.52x
P/B Ratio (Quarterly)1.37x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-27.98x
ROA (TTM)-56.11%
EV / EBITDA (TTM)38.45x
EPS Incl Extra (Annual)$-2.01
Current Ratio (Annual)6.38x
Quick Ratio (Quarterly)6.25x
3-Month Avg Trading Volume3.00M
52-Week Price Return-36.42%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.33
52-Week High$8.26
EPS Excl Extra (Annual)$-2.01
CapEx CAGR (5Y)-56.75%
Tangible BV CAGR (5Y)93.85%
26-Week Price Return14.33%
Quick Ratio (Annual)6.25x
13-Week Price Return-1.26%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)6.38x
Enterprise Value$364.93
Book Value / Share Growth (5Y)-20.88%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.74
3-Month Return Std Dev81.15%
Net Income / Employee (TTM)$-1
ROE (Last FY)-80.49%
Net Interest Coverage (Annual)-29.86x
EPS Basic Excl Extra (Annual)$-2.01
Total Debt / Equity (Quarterly)0.08x
EPS Incl Extra (TTM)$-2.01
ROI (TTM)-61.88%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.33
Price vs S&P 500 (52W)-71.52%
Year-to-Date Return11.40%
5-Day Price Return7.42%
EPS Normalized (Annual)$-2.01
ROA (5Y Avg)-46.83%
Month-to-Date Return9.22%
Cash Flow / Share (TTM)$-3.08
EBITD / Share (Annual)$-1.92
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.99%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.01
P/TBV (Quarterly)1.51x
P/B Ratio (Annual)1.37x
Book Value / Share (Annual)$2.56
Price vs S&P 500 (13W)-4.13%
Beta0.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-65.76%
52-Week Low$2.19
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.71
3.71
3.71
3.65
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RCKTRocket Pharmaceuticals, Inc. Common Stock | — | — | — | — | $3.86 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Rocket Pharmaceuticals is a late-stage biopharmaceutical company developing gene therapies for rare pediatric genetic diseases. Its pipeline includes five programs targeting Danon Disease, Fanconi Anemia, Leukocyte Adhesion Deficiency, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.